Medical - Healthcare Plans
Compare Stocks
4 / 10Stock Comparison
OSCR vs ALHC vs CNC vs CLOV
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
OSCR vs ALHC vs CNC vs CLOV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $4.71B | $3.74B | $26.15B | $1.35B |
| Revenue (TTM) | $11.70B | $4.26B | $198.10B | $1.92B |
| Net Income (TTM) | $-443M | $20M | $-6.44B | $-86M |
| Gross Margin | 77.6% | 9.0% | 14.9% | 103.6% |
| Operating Margin | -3.5% | 0.8% | -3.7% | -4.4% |
| Forward P/E | 32.9x | 140.1x | 16.4x | 62.6x |
| Total Debt | $430M | $338M | $18.78B | $0.00 |
| Cash & Equiv. | $2.77B | $578M | $17.89B | $78M |
OSCR vs ALHC vs CNC vs CLOV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Oscar Health, Inc. (OSCR) | 100 | 73.8 | -26.2% |
| Alignment Healthcar… (ALHC) | 100 | 82.7 | -17.3% |
| Centene Corporation (CNC) | 100 | 86.6 | -13.4% |
| Clover Health Inves… (CLOV) | 100 | 35.4 | -64.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OSCR vs ALHC vs CNC vs CLOV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OSCR is the clearest fit if your priority is momentum.
- +38.0% vs CLOV's -22.1%
ALHC carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
- 46.1% revenue growth vs CNC's 19.4%
- Combined ratio 1.0 vs CLOV's 1.0 (lower = better underwriting)
- 1.8% ROA vs CLOV's -15.8%
CNC is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 1 yrs, beta 0.39
- 74.6% 10Y total return vs ALHC's 5.7%
- Lower volatility, beta 0.39, Low D/E 93.6%, current ratio 1.68x
- Beta 0.39, current ratio 1.68x
CLOV lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 46.1% revenue growth vs CNC's 19.4% | |
| Value | Lower P/E (16.4x vs 62.6x) | |
| Quality / Margins | Combined ratio 1.0 vs CLOV's 1.0 (lower = better underwriting) | |
| Stability / Safety | Beta 0.39 vs OSCR's 1.84 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +38.0% vs CLOV's -22.1% | |
| Efficiency (ROA) | 1.8% ROA vs CLOV's -15.8% |
OSCR vs ALHC vs CNC vs CLOV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
OSCR vs ALHC vs CNC vs CLOV — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CNC leads in 3 of 6 categories
ALHC leads 2 • OSCR leads 0 • CLOV leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALHC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CNC is the larger business by revenue, generating $198.1B annually — 102.9x CLOV's $1.9B. Profitability is closely matched — net margins range from 0.5% (ALHC) to -4.4% (CLOV). On growth, CLOV holds the edge at +44.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $11.7B | $4.3B | $198.1B | $1.9B |
| EBITDAEarnings before interest/tax | -$379M | $66M | -$5.9B | -$84M |
| Net IncomeAfter-tax profit | -$443M | $20M | -$6.4B | -$86M |
| Free Cash FlowCash after capex | $1.1B | $237M | $6.3B | -$69M |
| Gross MarginGross profit ÷ Revenue | +77.6% | +9.0% | +14.9% | +103.6% |
| Operating MarginEBIT ÷ Revenue | -3.5% | +0.8% | -3.7% | -4.4% |
| Net MarginNet income ÷ Revenue | -3.8% | +0.5% | -3.3% | -4.4% |
| FCF MarginFCF ÷ Revenue | +9.0% | +5.6% | +3.2% | -3.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.2% | +33.3% | +7.1% | +44.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -100.0% | +2.1% | +18.3% | -112.5% |
Valuation Metrics
CNC leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $4.7B | $3.7B | $26.2B | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $2.4B | $3.5B | $27.0B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -10.62x | -4945.95x | -3.89x | -15.35x |
| Forward P/EPrice ÷ next-FY EPS est. | 32.94x | 140.08x | 16.40x | 62.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 77.35x | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.40x | 0.95x | 0.13x | 0.70x |
| Price / BookPrice ÷ Book value/share | 4.80x | 20.21x | 1.30x | 4.37x |
| Price / FCFMarket cap ÷ FCF | 4.45x | 33.04x | 6.05x | — |
Profitability & Efficiency
ALHC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ALHC delivers a 11.5% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-45 for OSCR. OSCR carries lower financial leverage with a 0.44x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALHC's 1.89x. On the Piotroski fundamental quality scale (0–9), ALHC scores 6/9 vs CLOV's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -45.2% | +11.5% | -28.6% | -27.7% |
| ROA (TTM)Return on assets | -7.0% | +1.8% | -7.9% | -15.8% |
| ROICReturn on invested capital | — | — | -21.6% | -34.0% |
| ROCEReturn on capital employed | -25.3% | +2.9% | -14.6% | -24.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.44x | 1.89x | 0.94x | — |
| Net DebtTotal debt minus cash | -$2.3B | -$240M | $889M | -$78M |
| Cash & Equiv.Liquid assets | $2.8B | $578M | $17.9B | $78M |
| Total DebtShort + long-term debt | $430M | $338M | $18.8B | $0 |
| Interest CoverageEBIT ÷ Interest expense | -23.85x | 1.27x | -9.03x | — |
Total Returns (Dividends Reinvested)
CNC leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CNC five years ago would be worth $8,112 today (with dividends reinvested), compared to $2,953 for CLOV. Over the past 12 months, OSCR leads with a +38.0% total return vs CLOV's -22.1%. The 3-year compound annual growth rate (CAGR) favors CLOV at 47.7% vs CNC's -8.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +19.8% | -9.5% | +26.8% | +8.3% |
| 1-Year ReturnPast 12 months | +38.0% | +18.2% | -11.4% | -22.1% |
| 3-Year ReturnCumulative with dividends | +150.2% | +165.6% | -22.6% | +222.2% |
| 5-Year ReturnCumulative with dividends | -24.0% | -31.9% | -18.9% | -70.5% |
| 10-Year ReturnCumulative with dividends | -48.4% | +5.7% | +74.6% | -74.4% |
| CAGR (3Y)Annualised 3-year return | +35.8% | +38.5% | -8.2% | +47.7% |
Risk & Volatility
CNC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CNC is the less volatile stock with a 0.39 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CNC currently trades 82.6% from its 52-week high vs CLOV's 66.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.84x | 0.75x | 0.39x | 1.22x |
| 52-Week HighHighest price in past year | $23.80 | $23.87 | $64.15 | $3.92 |
| 52-Week LowLowest price in past year | $10.69 | $11.63 | $25.08 | $1.58 |
| % of 52W HighCurrent price vs 52-week peak | +75.4% | +76.7% | +82.6% | +66.6% |
| RSI (14)Momentum oscillator 0–100 | 79.7 | 42.6 | 83.9 | 70.0 |
| Avg Volume (50D)Average daily shares traded | 6.2M | 3.6M | 5.7M | 5.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: OSCR as "Hold", ALHC as "Buy", CNC as "Buy", CLOV as "Hold". Consensus price targets imply 35.7% upside for ALHC (target: $25) vs -6.6% for OSCR (target: $17).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $16.75 | $24.83 | $51.00 | $3.33 |
| # AnalystsCovering analysts | 11 | 16 | 43 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.8% | +0.1% |
CNC leads in 3 of 6 categories (Valuation Metrics, Total Returns). ALHC leads in 2 (Income & Cash Flow, Profitability & Efficiency).
OSCR vs ALHC vs CNC vs CLOV: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is OSCR or ALHC or CNC or CLOV a better buy right now?
For growth investors, Alignment Healthcare, Inc.
(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus 19. 4% for Centene Corporation (CNC). Analysts rate Alignment Healthcare, Inc. (ALHC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OSCR or ALHC or CNC or CLOV?
Over the past 5 years, Centene Corporation (CNC) delivered a total return of -18.
9%, compared to -70. 5% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: CNC returned +85. 1% versus CLOV's -73. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OSCR or ALHC or CNC or CLOV?
By beta (market sensitivity over 5 years), Centene Corporation (CNC) is the lower-risk stock at 0.
39β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 369% more volatile than CNC relative to the S&P 500. On balance sheet safety, Oscar Health, Inc. (OSCR) carries a lower debt/equity ratio of 44% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — OSCR or ALHC or CNC or CLOV?
By revenue growth (latest reported year), Alignment Healthcare, Inc.
(ALHC) is pulling ahead at 46. 1% versus 19. 4% for Centene Corporation (CNC). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OSCR or ALHC or CNC or CLOV?
Alignment Healthcare, Inc.
(ALHC) is the more profitable company, earning -0. 0% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps -0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALHC leads at 0. 4% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 103. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is OSCR or ALHC or CNC or CLOV more undervalued right now?
On forward earnings alone, Centene Corporation (CNC) trades at 16.
4x forward P/E versus 140. 1x for Alignment Healthcare, Inc. — 123. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 35. 7% to $24. 83.
07Which pays a better dividend — OSCR or ALHC or CNC or CLOV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is OSCR or ALHC or CNC or CLOV better for a retirement portfolio?
For long-horizon retirement investors, Centene Corporation (CNC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
39)). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNC: +85. 1%, OSCR: -43. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between OSCR and ALHC and CNC and CLOV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.